Herr Dr Jason Loveridge, CEO 4 SC AG, spricht über die Produktpipeline und klinische Studien.
- 4SC is a biopharmaceutical company developing drugs that target cancer through epigenetic mechanisms – please explain in more detail.
- What does 4SC’s product pipeline look like and which clinical studies do you conduct at current?
- What is your vision for 2020?
Die Fragen im Einzelnen: